Literature DB >> 12461412

The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.

Xin Wei1, Chen Liang, Matthias Götte, Mark A Wainberg.   

Abstract

OBJECTIVE: To study the ability of HIV constructs containing the M184V substitution in reverse transcriptase (RT), which causes resistance to lamivudine, to evolve mutations that compensate for deletions within the HIV genome.
METHODS: Viruses containing deletions in non-coding regions of the viral genome were examined in tissue culture to see whether the additional presence of M184V delays the reestablishment of wild-type replication kinetics. Potential compensatory mutations were identified by sequencing, and site-directed mutagenesis was carried out to confirm the biological relevance of such substitutions. The rate of initiation of reverse transcription was measured using either recombinant wild-type RT or RT containing M184V.
RESULTS: M184V-containing viruses were unable to undergo compensatory mutagenesis to reestablish wild-type replication kinetics, whereas viruses that did not contain M184V were able to mutate extensively. This ability was demonstrated most extensively in viruses deleted of an "A-rich loop", located upstream of the primer-binding site, which is involved in initiation of reverse transcription. The rate of such initiation was severely diminished in virus containing the RT enzyme carrying the M184V substitution. This inhibitory effect was significantly enhanced in a biochemical system that included both the M184V mutant enzyme and a viral DNA template that contained the deletion in the A-rich loop.
CONCLUSIONS: These findings provide further biological and biochemical evidence that M184V-containing viruses are impaired in replication fitness. Viruses that had the A-rich-loop deleted were able to reestablish replication ability quickly in the wild-type RT, which provides further evidence for the plasticity of the HIV genome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12461412     DOI: 10.1097/00002030-200212060-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia.

Authors:  Adam W Bartlett; Pagakrong Lumbiganon; Nia Kurniati; Tavitiya Sudjaritruk; Thahira J Mohamed; Rawiwan Hansudewechakul; Penh S Ly; Khanh H Truong; Thanyawee Puthanakit; Lam V Nguyen; Kulkanya Chokephaibulkit; Viet C Do; Nagalingeswaran Kumarasamy; Nik Khairulddin Nik Yusoff; Moy S Fong; Dewi K Watu; Revathy Nallusamy; Annette H Sohn; Matthew G Law
Journal:  J Adolesc Health       Date:  2019-08-05       Impact factor: 5.012

3.  The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.

Authors:  Hong-Tao Xu; Yudong Quan; Susan M Schader; Maureen Oliveira; Tamara Bar-Magen; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

4.  Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Authors:  Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

5.  Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Authors:  Guangwei Yang; Elijah Paintsil; Ginger E Dutschman; Susan P Grill; Chuan-Jen Wang; Jimin Wang; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

6.  Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.

Authors:  Karidia Diallo; Bruno Marchand; Xin Wei; Luciano Cellai; Matthias Götte; Mark A Wainberg
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 7.  Evaluation and treatment of the patient coinfected with hepatitis B and HIV.

Authors:  Ellen Kitchell; Mamta K Jain
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

8.  Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.

Authors:  Véronique Joly; Diane Descamps; Gilles Peytavin; Fatiha Touati; France Mentre; Xavier Duval; Séverine Delarue; Patrick Yeni; Françoise Brun-Vezinet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

9.  Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Authors:  Barbara A Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Journal:  Viruses       Date:  2012-08-07       Impact factor: 5.048

10.  Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.

Authors:  Hong-Tao Xu; Yudong Quan; Eugene Asahchop; Maureen Oliveira; Daniella Moisi; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-10-07       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.